Mechanisms governing the function of Forkheadbox A1 (FOXA1), a member of the FOX class of transcription factors, have been extensively studied. However, little is known about the activities and expression pattern of FOXA1 in endometrial cancer (EC). In the present study, we investigated the level of FOXA1 in multiple human EC cell lines and clinical samples by immunohistochemistry, qRT-PCR and Western blot analysis. FOXA1 overexpression was observed in estrogen receptor (ER)α-positive EC cell lines (P=0.0048). In endometrial tissues, FOXA1 was significantly upregulated in both normal endometrium and well-differentiated endometrial cancer tissues (P<0.001). Functional analyses of FOXA1 were evaluated by MTT, plate colony formation and Transwell assay. The results revealed that forced expression of FOXA1 inhibited EC cell proliferation, whereas FOXA1 depletion promoted cell viability and was associated with tumorigenesis. The nude mouse tumor xenograft assay also confirmed that ablation of FOXA1 expression promoted cell proliferation. Furthermore, we found that knockdown of FOXA1 decreased the expression of ERα, and FOXA1 interacted with this receptor in the EC cell lines. Collectively, these experiments suggest that FOXA1 is a tumor suppressor in EC and has a possible interaction with ERα.
Introduction
Endometrial cancer (EC) is one of the most common gynecological malignancies, with an escalating number of new cases and an increasing mortality rate. In the US, ~49,500 new cases of EC will be diagnosed in 2013, and 8,200 deaths are expected (1) . Accurate regulation of complex transcriptional programs is central to the progression of EC. Forkhead-box A1 (FOXA1) a member of the FOX family of transcription factors (TFs) that comprises at least 40 members (2), was originally identified for its transcriptional role in early liver and pancreas development (3) . At present, FOXA1 is mainly known as a 'pioneer factor', which can occupy distal regulatory enhancers and alter the chromatin accessibility for subsequent recruitment of collaborating TFs, instead of directly promoting transcription activation (4, 5) . However, the functional role of FOXA1 in EC remains unclear.
Estrogen receptor α (ERα) is a ligand-activated transcription factor that belongs to the nuclear receptor superfamily (6) , and regulates estrogenic action in the female reproductive tract. Upon estrogen stimulation, ERα binds at numerous genomic loci to promote the transcriptional program (7), while several coregulators are simultaneously recruited to the chromosomal loops to facilitate the estrogenic transcriptional response (8) (9) (10) (11) . Thus, ERα is an ideal target for etiologyspecific therapy in EC. Decreased or absent expression of ERα is regarded to be accompanied by disease progression, but the underlying mechanism is still unclear (12) .
A number of studies have reported FOXA1 upregulation in several types of human cancers, including breast cancer, in which the expression patterns of FOXA1 are strikingly similar to that of ERα (13) . We speculated that in endometrial cancer, a disease also closely related to hormone and hormone receptors, FOXA1 may play a potential role in cancer progression and may regulate the transcriptional activation of ERα. In the present study, we investigated the level of FOXA1 in multiple human EC cell lines and clinical samples. The expression of FOXA1 in normal endometrial and EC tissues was analyzed and correlated with clinicopathological parameters. The regulatory roles of FOXA1 were investigated both in vitro and in vivo. These experiments suggest that FOXA1 is a tumor suppressor in EC. Furthermore, our results increased our understanding of the ERα/FOXA1 relationship, and we propose that FOXA1 may act as a regulator of the ER signaling pathway in EC cell lines. Immunohistochemical analysis. All samples were prepared and analyzed with the Histostain-Plus kit (rabbit) (MRBiotech, Emeryville, CA, USA) according to the manufacturer's protocol. After dewaxing and hydration, 4-µm sections from FFPE tissue were treated by boiling in sodium citrate (pH 6.0) for 20 min for antigen retrieval, and endogenous peroxidase activity was blocked by incubation in 0.3% H 2 O 2 in methanol for 10 min. Nonspecific binding of antibodies was blocked with serum for 15 min. The slides were then incubated with rabbit polyclonal anti-FOXA1 antibody (1:200; Abcam, Cambridge, MA, USA) for 24 h at 4˚C. The sections were incubated with a biotinylated secondary antibody (MRBiotech). Then the sections were treated by an horseradish peroxidase-conjugated avidin-biotin complex. Following the manufacturer's instructions, samples were detected by DAB to ensure the intensity of FOXA1 expression. We used the methods of Badve et al to score the staining intensity (15) . Briefly, the percentage of staining was classified as '0' when there was no nuclear expression, '1' for up to 10% positive tumor nuclei, '2' for 11-20% and continuing in the same manner until a maximum score of '10'. Intensity was scored as '+,' '++', and '+++' for weak, moderate, and strong staining, respectively. The percentage (P) and intensity (I) of nuclear expression were multiplied to generate a numerical score (S = P x I). As a positive control, a section of breast cancer tissue was immuno stained with anti-FOXA1 in the same manner. As a negative control, phosphate-buffered saline (PBS) was used to replace the primary antibody. ERα expression status was confirmed in the same manner. Clinical and pathological data relating to the clinical samples are presented in Table I . RNA extraction and quantitative real-time PCR. Total RNA was prepared from the EC cell lines using TRIzol RNA isolation reagents (Invitrogen, Carlsbad, CA, USA). The cDNA was generated with the Prime Script RT reagent kit (Takara Inc., Otsu, Japan). A 50-µl PCR amplification of single-strand cDNA was performed with 40 cycles of denaturation (94˚C) for 60 sec, annealing (55˚C) for 30 sec, and elongation (72˚C) for 30 sec using SYBR Premix Ex Taq (Takara Inc.). The primer sequences are listed in Table II . For all the data, values Table I . Correlation of FOXA1 expression with clinicopathological parameters of the endometrial carcinoma cases. Western blot analysis. Cells were lysed for total protein extraction using ProteoJET Mammalian Cell Lysis Reagent (MBI Fermentas, Ontario, Canada) including a protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Protein (80 µg) was loaded onto precast 4% stacking, 10% Tris-glycine gels and separated by gel electrophoresis. Proteins in the gels were then transferred to a polyvinylidene difluoride (PVDF) membrane. After transfer, membranes were blocked with 5% bovine serum albumin (BSA)/phosphate-buffered saline (PBS) for 3 h. The membranes were incubated with primary antibodies at 4˚C overnight. The membranes were then incubated with peroxidase-linked secondary antibody (1:10,000; Epitomics, Burlingame, CA, USA) for 2 h at room temperature. The blotted proteins were visualized using an ECL kit (Beyotime, China), scanned and analyzed with TotalLab software.
Primary antibodies included: rabbit anti-FOXA1 (1:1000; Abcam), rabbit anti-ERα (1:2000; Epitomics) and rabbit anti-β-actin (1:7500; Epitomics)
Plasmid and transfection. To stably express FOXA1, HEC-1B cells were washed with PBS and switched to antibiotic-free growth medium for 24 h before transfection. All transfections used Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. The plasmid pCMV6/ GFP/Neo-FOXA1 (Genechem, Shanghai, China) containing transfection-ready FOXA1 cDNA (GenBank: NM_004496) was transfected into HEC-1B cells and then the cells were selected with G418 (800 µg/ml; Gibco, Carlsbad, CA, USA) in the growth medium and resistant clones were chosen.
To stably silence FOXA1, Ishikawa cells were transfected with shFOXA1 (pGLV/h1/GFP/puro-FOXA1; Shanghai Genepharma Ltd., China) (5'-GAGAGAAAAAAUCAAC AGC-3') and were then selected with puromycin (0.5 µg/ml; Sigma Chemical, St. Louis, MO, USA). RL95-2 cells were transiently transfected with shFOXA1 in the absence of selection pressure.
For the negative controls, HEC-1B cells were transfected with a pure pCMV6/GFP/Neo vector, and Ishikawa and RL95-2 cells were transfected with the pGLV/h1/GFP/puro vector, respectively, under the same culture conditions.
To evaluate the effects of ERα expression and silencing, Ishikawa and HEC-1B cells were transiently transfected with ERα and shERα plasmids as described above, the ERα-expressing vector (RG213277) and control vector (PS10010), the plasmid encoding ERα silencing short hairpin RNA (shRNA) (sh-ERα, GI378604), and the controls (sh-NC, TR3008) (all purchased from OriGene Technologies, Beijing, China). The transfection efficiency was verified by realtime quantitative reverse-transcription PCR (qRT-PCR) and western blotting.
Cell migration assay. Cell migration activity was accomplished using Boyden chambers containing polycarbonate filters with an 8-µm pore size (Millipore). Cells (5x10 4 cells/well) were resuspended with serum-free medium in the upper chamber. Medium containing 10% fetal bovine serum was added to the lower chamber. After incubation at 37˚C for 24 h, cells on the upper side of the membrane were removed using sterile cotton swabs. Cells adhering to the lower surface were fixed with 100% methanol and stained with hematoxylin, scanned and digital images were obtained with an Aperio Scanscope System (Aperio Technologies, USA) at a magnification of x200. Five random fields were selected for each membrane, and results are expressed in terms of the number of migratory cells per field. Each experiment was conducted in triplicate and repeated at least three times.
Cell invasion assay. Cell invasive activity was assessed using a BD BioCoat Matrigel Invasion Chamber (BD Biosciences, USA) according to the manufacturer's instructions. Cells (1x10 5 cells/well) were resuspended with serum-free medium in the upper chamber with a thin layer of Matrigel matrix. Medium containing 10% FBS was added to the lower chamber. After incubation at 37˚C for 72 h, cells that had migrated through the membrane were fixed, stained and counted as described above.
Proliferation assay. Cells (3x10 3 cells/well) were plated in 96-well plates. Cell number was measured every 24 h via a colorimetric assay with 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Sigma). Absorbance at 490 nm was evaluated with a microplate reader (Model 680, Bio-Rad, USA). Medium was changed every other day. For the plate colony formation assay, 800 cells/well were seeded into 6-well plates. The cells were fixed and stained with crystal violet when clearly identifiable cell clones had formed. Results were detected under a light microscope. Each experiment was repeated at least three times, and assessed in triplicate.
Co-immunoprecipitation of FOXA1 and ERα. Nuclear protein lysates were prepared at a concentration of 1 µg/µl from Ishikawa and RL95-2 EC cell lines. These lysates were incubated with 10 µg anti-FOXA1 (Abcam). The immunoprecipitated proteins were collected using protein A/protein G agarose beads (Beyotime), washed with PBS and resuspended in loading buffer. The boiled samples were separated by SDS-PAGE, transferred to a PVDF membrane and probed with 
Statistics. Each experiment was completed at least three times, and all tests were carried out with Statistical Package for the Social Science (SPSS) software version 17.0 (Chicago, IL, USA). Data represent the mean with standard deviation (SD). Data were compared using the two-tailed Student's t-test or Mann-Whitney U-test for multiple comparisons. Differences having a probability of p<0.05 were regarded as statistically significant.
Results

Expression of FOXA1 in tissues and its association with clinicopathological parameters.
To assess whether FOXA1 is commonly upregulated in tissues, we compared its level in normal endometrial samples, atypical complex hyperplasia, and EC tissues using immunohistochemistry. Breast cancer tissues were immunostained as a positive control. The results showed that FOXA1 expression was restricted to the nucleus with little or no cytoplasmic staining (Fig. 1A) . We found strong staining in normal endometrium. In contrast, staining was moderate or weak in atypical complex hyperplasia and EC tissues.
To investigate whether the change in FOXA1 expression of EC was associated with any of the clinical characteristics, we compared the association of FOXA1 expression levels with the clinicopathological parameters of the EC cases (Table I) . We calculated a composite histoscore to account for both staining intensity and uniformity. Compared to the atypical hyperplasia, and EC tissues, normal endometrial tissues expressed the highest levels of FOXA1 ( Fig. 1B; H-score=19.02; p<0.001). In EC tissues, strong staining of FOXA1 was observed in early-stage EC ( Fig. 1A ; H-score=11.35; p=0.001), whereas advanced-stage cancers had a weaker FOXA1 expression ( Fig. 1A ; H-score=5.00; p=0.001). FOXA1 expression was also correlated with histologic type (p<0.001), with serous tumors (H-score=4.50) showing lower FOXA1 scores when compared with the endometrial endometrioid carcinomas (H-score=11.76). Furthermore, the status of FOXA1 was positively associated with ER levels, suggesting that FOXA1 expression has prognostic significance within the context of ER expression (p<0.0001). All of these results indicate that FOXA1 is a tumor suppressor in EC, and its expression level is a favorable prognostic and diagnostic marker.
FOXA1 expression in human EC cell lines.
To confirm the expression of FOXA1 in EC, 4 human EC cell lines (Ishikawa, RL95-2, HEC-1B and AN3CA) were used. Analysis of FOXA1 expression by qRT-PCR (Fig. 1C) and western blotting (Fig. 1D) revealed that there was a high endogenous FOXA1 expression in Ishikawa and RL95-2 cells, which are derived from welldifferentiated local endometrial adenocarcinoma (16, 17) . In contrast, HEC-1B cells, which are derived from moderately well-differentiated endometrial adenocarcinoma (18) had relatively low FOXA1 expression among the cancer cell lines (p=0.0048).
Suppression of EC cell proliferation, migration and invasion by FOXA1.
To determine whether loss of FOXA1 has an effect on EC cells, Ishikawa and RL95-2 cells were transiently transfected with a vector encoding a short hairpin RNA (shRNA) against FOXA1 and its corresponding negative control. After 48 h, RNA was extracted and analyzed by qRT-PCR, and the protein expression was examined after 72 h. As shown in Fig. 1E , the inhibitory efficiency of FOXA1 was ~50-70% in Ishikawa and RL95-2 cells (p<0.01 and p<0.001, respectively).
We used the MTT assay to determine whether depletion of FOXA1 induced cell proliferation; a statistically significant induction of cell proliferation was detected in two EC cell lines (Fig. 2A) . The results revealed that FOXA1 depletion promoted cell proliferation in Ishikawa and RL95-2 cells in a time-dependent manner. To further explore the role of FOXA1 in cell growth, we carried out plate colony formation assays. Ishikawa and RL95-2 cells formed more colonies when transfected with shFOXA1 than with the control vector (p<0.01; Fig. 2B ). Additionally, Transwell migration (data not shown) and invasion assays (Fig. 2C) were performed to investigate the migratory and invasive potential of EC cells. FOXA1 depletion markedly promoted cell migration and invasion in Ishikawa and RL95-2 cells (p<0.001).
In comparison with the effect of FOXA1 knockdown, restoring FOXA1 expression in HEC-1B cells had an opposite effect. Successful reestablishment of FOXA1 expression in HEC-1B cells was confirmed by qRT-PCR and western blotting (p<0.001; Fig. 1F ). After 72 h of incubation, HEC-1B cells stably transfected with the FOXA1 expression plasmid showed significant growth inhibition when compared with the negative control cells (p<0.01; Fig. 2A and B) . Moreover, FOXA1 plasmid transfection decreased the migratory and invasive potential of HEC-1B cells (p<0.001, Fig. 2C ). All of the in vitro experiments suggest that FOXA1 plays an essential role in inhibiting EC progression.
Oncogenic role of FOXA1 in an in vivo tumor xenograft model.
To further assess the role of FOXA1 in the progression of EC, we performed tumorigenicity assays in nude mice. We used shRNA-mediated stable knockdown of FOXA1 in Ishikawa cells (Fig. 3A) , and the cells were injected subcutaneously. Tumors formed 1 week after injection. Over a 5-week period, we observed higher tumor growth rates in the mice injected with the cells transfected with shFOXA1 compared with the tumor growth in the negative control group (p<0.01, Fig. 3C ). Five weeks after injection, tumors were completely removed from the mice. The final mean weight and volume of the tumors were markedly higher in the shFOXA1 group than in the negative control group (p<0.05 and p<0.001; Fig. 3B ). To explore whether shFOXA1 influences the proliferative capacity of Ishikawa cells, we compared the levels of Ki-67 in the two groups. Previous studies revealed that expression of Ki-67 is associated with cell proliferation (19) . As shown in Fig. 3D , Ki-67 was upregulated in the shFOXA1 group (p<0.01). Furthermore, ERα expression was downregulated in the shFOXA1 group (p<0.01). Taken together, these results suggest an important role for FOXA1 in regulating tumor viability in EC.
FOXA1 regulates the ER signaling pathway. Consistent with several reports that describe FOXA1 as a regulator of ER activity (20) , our experiments used Ishikawa and RL95-2 cells as they express easily detectable levels of both FOXA1 and ERα (data not shown). FOXA1 knockdown by shRNA revealed a significant decrease in the expression of ERα-dependent pS2 and GREB1 genes in the Ishikawa and RL95-2 cells in response to 10 nM estradiol (Fig. 4A) . Additionally, we found that FOXA1 depletion abolished the expression of ERα at the mRNA and protein levels (p<0.05, Fig. 4B ). We also examined whether FOXA1 overexpression promotes ERα expression in FOXA1-overexpressing HEC-1B cells, an EC cell line with relatively low ERα expression. As shown in Fig. 4C , an increased FOXA1 level was correlated with higher ER mRNA and protein levels (p<0.05). These results revealed that FOXA1 regulated endogenous ERα expression in the three EC cell lines at the post-transcriptional level. To ascertain whether ERα influences the FOXA1 level, we performed a reciprocal experiment. After inhibition or upregulation of the expression of ERα, we found no significant difference in FOXA1 expression (data not shown), confirming that FOXA1 acts upstream of ERα. We next sought to determine whether FOXA1 and ERα interact with each other by exploring endogenous FOXA1 and ERα immunoprecipitates from Ishikawa cells with the reciprocal antibodies. As shown in Fig. 4D , we found an interaction between the two proteins, which demonstrated that there was a cell-specific correlation between these two genes, supporting an involvement of FOXA1 in the ER signaling pathway.
To further assess the role of FOXA1 in the estrogeninduced growth in EC cells, we transfected HEC-1B cells with a FOXA1 expression plasmid, and the proliferation assay was completed in phenol red-free medium containing 10% charcoal/dextran-treated FBS. The results showed that the EC cells expressing FOXA1 no longer proliferated following estrogen stimulation (p<0.001, Fig. 4E ), suggesting a functional role for FOXA1 in mediating the response to estrogen in EC. 
Discussion
Endometrial cancer involves a heterogeneous group of tumors. Early-stage type I endometrioid tumors are often treated using adjuvant radiotherapy (21) , whereas similarly staged type II serous tumors are treated with chemotherapy. Therefore, an accurate classification determines the appropriate adjuvant therapy. However, high-grade serous and endometrioid endometrial carcinomas are difficult to accurately subtype, and intraobserver concordance among specialized pathologists is low (22) (23) (24) . Thus, the molecular classification of endometrial carcinomas may be a novel method by which to carry out informed treatment decisions.
The FOX family, particularly FOXA1, plays an important role in organ morphogenesis and disease progression (25) . However, the role of FOXA1 expression or activity in EC is still unclear. A previous study investigated the expression pattern of FOXA1 in EC tissues, yet the samples of normal endometrium and the precise mechanism remain to be further explored (26) . In the present study, we found that FOXA1 was present in almost all normal endometrial tissues, whereas differential expression was observed among the EC tumor types. We confirmed that FOXA1 can be detected in earlysatge endometrial endometrioid carcinomas more frequently than in advanced-stage cancers, including endometrioid carcinomas and serous tumors. Furthermore, the FOXA1 level was correlated with the depth of myometrial invasion and lymph node metastasis of EC, which are important prognostic factors (27) . More importantly, we found a significantly positive correlation between FOXA1 and ERα in EC tissues, and the promotive effect of FOXA1 on ERα was proven in EC cell lines. This expression analysis revealed that FOXA1 was more highly expressed in well-differentiated tumors, which can provide a clinically effective prognostic factor particularly in low-risk EC patients, among ERα-positive cases.
Over the past decade, FOXA1 expression has been reported in several types of human cancers, and the results suggest it has a dual function. Briefly, the FOXA1 level is increased in acute myeloid leukemia, esophageal cancer and lung cancer, and acts as an oncogene (28, 29) . In contrast, in human hepatocellular carcinoma, bladder cancer, pancreatic and luminal subtype A breast cancer, FOXA1 inhibits metastasis and is a favorable prognostic factor (30) (31) (32) (33) . In the present study, we confirmed that FOXA1 overexpression in HEC-1B cells decreased cellular invasion and migration, and completely prevented estrogeninduced proliferation, whereas its depletion in Ishikawa and RL95-2 cells promoted cell viability and was associated with tumorigenicity. FOXA1 was first reported to act as a growth inhibitor through activation of the transcription of p27 in breast cancer (34) . Subsequent studies revealed that FOXA1 is associated with cyclin-dependent kinase inhibitors (13, 35) , which may explain the anti-proliferative capacity of FOXA1 in EC. In addition, our xenograft experiments showed that ablation of FOXA1 expression promoted the proliferative ability of Ishikawa cell. For several diseases, loss of FOXA1 expression promotes tumorigenesis or increases the level of tumor aggressiveness (32) . All of these findings were confirmed in our study and suggest that FOXA1 acts as a tumor suppressor in EC.
An increasing number of studies suggest that crosstalk between ER and signal transduction pathways is a potential factor in the proliferation of ERα-positive EC cells and endocrine resistance (36, 37) . It has been well established that FOXA1 binding parallels ERα binding in both accessible and inaccessible regions, revealing that FOXA1 is a key determinant of ER function and endocrine response in breast cancer (20) . Critically, one important issue raised by our experiments is that the expression pattern of FOXA1 in EC are strikingly similar to that of ERα. Hence, we speculated that decreased ERα expression (or its absence) during disease progression may be due to loss of FOXA1 function. FOXA1 depletion in vitro significantly decreased pS2 and GREB1 expression, which indicates that FOXA1 is a key regulator of ERα gene transcription. Furthermore, specific silencing of FOXA1 was found to lead to the discrepancy of ERα mRNA and protein levels in the multiple EC cell lines tested. To further understand the role of FOXA1 in the ERα signaling pathway of EC, co-immunoprecipitation was performed and we found an interaction between the two proteins. The comparable effects of FOXA1 and ERα suggest that the two proteins may cooperatively regulate the transcriptional networks previously ascribed to ERα alone. These findings are consistent with previous studies concerning breast cancer and confirm the involvement of FOXA1 in the ERα signaling pathway.
A number of studies have reported that FOXA1 acts as a 'pioneer factor'. It can mimic a linker histone and can bind directly to condensed chromatin (38, 39) . This raises the possibility that FOXA1 may provide the opportunity for other TFs to associate with chromatin. Several lines of evidence have provided an indication of the mechanistic complexity required for acute transcriptional control of steroid hormone receptors (8, 40) . Of note, imbalanced activity of several co-regulator proteins has been proven to cause endocrine therapy-resistance, suggesting that future therapies for hormone-related diseases may target additional components of the steroid hormone receptors (41) . Although our present understanding of whether FOXA1 is involved in ERα-regulated gene transcription in endometrial cancer is limited, emerging evidence implicates an important role for FOXA1 in disease therapy (42) . However, there are many TFs which may regulate the progression of endometrial cancer; therefore our team is investigating whether FOXA1 affects the function of other steroid receptors, including progesterone receptor, androgen receptor and glucocorticoid receptor, which may establish a foundation for future application of FOXA1 in the treatment of EC.
In summary, our findings confirm that FOXA1 is a valuable prognostic factor in EC, and a positive relationship exists between FOXA1 and ERα. Further reasearch concerning FOXA1 in the steroid receptor signaling pathway for the treatment of EC is warranted.
